Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...
Vertex Pharmaceuticals gets CHMP opinion recommending Kaftrio label expansion
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
precisionmedicineonline17h
CHMP Recommends Vertex's Kaftrio, Kalydeco Combo for Additional Cystic Fibrosis Patients
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
pharmaphorum1d
Celebrations as NHS England agrees deal for Vertex’ cystic fibrosis triple
Kaftrio is the first drug that works in patients with the F508del and MF mutations, who account for around 90% of the overall CF population, and in trials led to improved lung function as well as ...
Zacks.com on MSN17d
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, missing the Zacks Consensus Estimate of $3.99. The bottom line declined 5.2% on a ...
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
In the realm of gene-editing therapies, Vertex has launched Casgevy, an ex-vivo gene-edited cell therapy for the severe blood disorders sickle cell disease and transfusion-dependent beta-thalassemia.
Yahoo Finance23d
Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?
Vertex’s cystic franchise (“CF”) sales continue to grow, driven by higher sales of its blockbuster CF medicine, Trikafta/Kaftrio (Trikafta’s brand name in Europe), in younger age groups.